?Protein Technology Shared Resource The goal of the Protein Technology Shared Resource (PTSR) is to generate protein reagents and provide analytical instrumentation that enables SJCCC members to explore the biology and therapeutic consequences of altered protein function in cancer. The PTSR offers state-of-the-art technologies for protein expression and purification from bacteria, insect cells, and mammalian host systems, and provides expert consultation to SJCCC members regarding their needs for these services. The core has recently upgraded its protein expression pipeline by acquiring contemporary automated protein purification systems to enhance the quality of the final product and the documentation of its purity. The PTSR was founded and has been directed by Charles Rock, PhD, an expert in protein expression and purification. Moving forward, the leadership of the PTSR is transitioning in the next funding period to Charalampos Kalodimos, PhD (CBP), the new Chair of the Department of Structural Biology. Kalodimos has decades of experience in protein biochemistry and brings new energy and vision to enhancing the impact of the PTSR on SJCCC research. Currently, Rock and Kalodimos are co- directing the PTSR for one year to ensure a smooth transition in leadership. When new components are fully integrated into the PTSR, the resource will have 9 technical staff, 1 manager, and the Director (Kalodimos). The PTSR is a highly specialized Shared Resource that provides a relatively small but crucial service with a significant impact on the science of the SJCCC. The centralization of resources for protein production, purification, and analysis provides economic value to SJCCC members, and the PTSR can usually offer substantial savings even for commercially available proteins. Cytokines, for example, cost $10 to $30 per microgram commercially, whereas PTSR recently produced 250 micrograms of M-CSF for Kanneganti (CBP) for $0.50 per microgram, saving hundreds of thousands of dollars. Of the 26 manuscripts using the PTSR, 7 (27%) involved intraprogrammatic collaboration, and 4 (15%) involved interprogrammatic collaboration. Work involving the PTSR has had marked scientific impact, including publications from 4 of the 5 Programs, CBP (n=20), DBSTP (n=7), HMP (n=3), and NBTP (n=1). In the upcoming funding period, the PTSR will continue to offer bacterial, insect, and mammalian cell expression systems for protein production, supported by existing fermentation equipment and cell culture facilities. The transition in Directors will be completed, and services will be significantly expanded and improved, including expansion of the protein-expression capabilities and the integration of the molecular-interaction components. State-of-the art cloning and expression services will be augmented by the addition of a Hudson Robotics ProLink Protein Expression System capable of performing high-throughput expression screens of multiple clones, which will be operational by July 2018.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA021765-41
Application #
9883745
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-03-01
Budget End
2021-02-28
Support Year
41
Fiscal Year
2020
Total Cost
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Gibson, Todd M; Li, Chenghong; Armstrong, Gregory T et al. (2018) Perceptions of future health and cancer risk in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Cancer 124:3436-3444
Yang, Kai; Blanco, Daniel Bastardo; Chen, Xiang et al. (2018) Metabolic signaling directs the reciprocal lineage decisions of ?? and ?? T cells. Sci Immunol 3:
Ferrolino, Mylene C; Mitrea, Diana M; Michael, J Robert et al. (2018) Compositional adaptability in NPM1-SURF6 scaffolding networks enabled by dynamic switching of phase separation mechanisms. Nat Commun 9:5064
Bjornard, Kari L; Gilchrist, Laura S; Inaba, Hiroto et al. (2018) Peripheral neuropathy in children and adolescents treated for cancer. Lancet Child Adolesc Health 2:744-754
Luo, Yi; Shao, Lijian; Chang, Jianhui et al. (2018) M1 and M2 macrophages differentially regulate hematopoietic stem cell self-renewal and ex vivo expansion. Blood Adv 2:859-870
Peterson, Rachel K; Ashford, Jason M; Scott, Sarah M et al. (2018) Predicting parental distress among children newly diagnosed with craniopharyngioma. Pediatr Blood Cancer 65:e27287
Kumar, Rahul; Liu, Anthony P Y; Orr, Brent A et al. (2018) Advances in the classification of pediatric brain tumors through DNA methylation profiling: From research tool to frontline diagnostic. Cancer 124:4168-4180
Rusch, Michael; Nakitandwe, Joy; Shurtleff, Sheila et al. (2018) Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptome. Nat Commun 9:3962
Kurmasheva, Raushan T; Kurmashev, Dias; Reynolds, C Patrick et al. (2018) Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 65:
Chamdine, Omar; Elhawary, Ghada Ahmad Saad; Alfaar, Ahmad Samir et al. (2018) The incidence of brainstem primitive neuroectodermal tumors of childhood based on SEER data. Childs Nerv Syst 34:431-439

Showing the most recent 10 out of 6764 publications